This series is designed help allergists and other allergy and asthma providers to stay abreast of recent developments in the field of allergy and asthma.
- Diagnosing and Living with COPD
- Nasal Polyps - Seminar on Sinuses, Symptoms and Science
- Type 2 Inflammation - Severe Asthma and Co-Morbidities
- Vaping - What We Need to Know
- The Next Steps in Peanut Allergy
- Inhaler Innovation and History: What is the Right Choice for You?
- Asthma Disparities and Differential Responses to Therapy
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support (Only include if there is commercial support)
There is no commercial support for this activity
Primary Care Providers
By participating in these webinars, learners should be able to:
- Identify recent developments in allergy and asthma
- Translate clinical science principles to clinical practice in patients with asthma and allergic diseases
- Evaluate diagnostic and therapeutic strategies for treating patients with asthma and allergic diseases
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an "ineligible company" as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been resolved.
Michael Blaiss, MD, Planner
Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Gary Steven, MD, Presenter
Consultant/Consulting fee: Aimmune, ALK, Regeneron
Tanya Laidlaw, MD, (Speaker)
Advisory board member/consultant; Sanofi/Regeneron; Consultant/consulting fee - Novartis
Bradley Chipps, MD Speaker
Consultant/Speaker: Astra Zeneca, Circassia, Genentech, Novartis, Regeneron, Sanofi, Teva
Todd Mahr, MD, Speaker
Speaker/Advisory/Honorarium: ALK, GSK, Kaleo, Sanofi, AstraZeneca, Boehringer-Ingelheim, Renegeron, Stellargenes Greer
Julie Wang, MD
Research grants/Consultant: Aimmune, DBV, Regeneron, ALK Abello
J. Allen Meadows, MD, Speaker
Advisory board, Consulting fees: GlaxoSmithKline, Greer, Aimmune
Speaker, honorarium: Optinose, Pfizer, Astra Zeneca
Leroy Graham, MD, Speaker
Speaker/Honoraria: Teva, Integrity CE, ThermoFisher
Co-chair/Advisory Board: Sanofi/Gemzyme